Igor Puzanov
Director, Early Phase Clinical Trials
Research Interests
Make your next move.
Prepare your application
Review drafts before you send them.
Explore related searches
Articles (14)
Year:
2025
Year:
2025
PURPOSE Current guidelines for the management of metastatic non–small cell lung cancer (NSCLC) without driver mutations recommend checkpoint immunotherapy with PD-1/PD-L1 inhibitors, either alone or in combination with chemotherapy. This approach fails to account for individual patient variability and host immune factors and often results in less-than-ideal outcomes. To address the limitations of the current guidelines, we developed and subsequently blindly validated a machine learning algorithm using pretreatment plasma proteomic profiles for personalized treatment decisions. PATIENTS AND METHODS We conducted a multicenter observational trial (ClinicalTrials.gov identifier: NCT04056247 ) of patients undergoing PD-1/PD-L1 inhibitor–based therapy (n = 540) and an additional patient cohort receiving chemotherapy (n = 85) who consented to pretreatment plasma and clinical data collection. Plasma proteome profiling was performed using SomaScan Assay v4.1. RESULTS Our test demonstrates a strong association between model output and clinical benefit (CB) from PD-1/PD-L1 inhibitor–based treatments, evidenced by high concordance between predicted and observed CB ( R 2 = 0.98, P < .001). The test categorizes patients as either PROphet-positive or PROphet-negative and further stratifies patient outcomes beyond PD-L1 expression levels. The test successfully differentiates between PROphet-negative patients exhibiting high tumor PD-L1 levels (≥50%) who have enhanced overall survival when treated with a combination of immunotherapy and chemotherapy compared with immunotherapy alone (hazard ratio [HR], 0.23 [95% CI, 0.1 to 0.51], P = .0003). By contrast, PROphet-positive patients show comparable outcomes when treated with immunotherapy alone or in combination with chemotherapy (HR, 0.78 [95% CI, 0.42 to 1.44], P = .424). CONCLUSION Plasma proteome–based testing of individual patients, in combination with standard PD-L1 testing, distinguishes patient subsets with distinct differences in outcomes from PD-1/PD-L1 inhibitor–based therapies. These data suggest that this approach can improve the precision of first-line treatment for metastatic NSCLC.
Year:
2024
Year:
2024
Year:
2024
Year:
2024
Year:
2024
Year:
2023
Year:
2023
Year:
2023
Year:
2023
Year:
2023
Year:
2023
Year:
2023
Collaborators (20)
Chen Hu
Associate Professor
Johns Hopkins University School of Medicine
David Carbone
Ohio State University Medical Center
Theodore Logan
Associate Professor Clinical Medicine
Indiana University School of Medicine
Lei Deng
Assistant Professor
Fred Hutch Cancer Center
george weiner
University of Iowa Healthcare
Adam Dicker
Professor & Chair
Thomas Jefferson University
Andrea Kasinski
Assistant Professor
Purdue University
John Kirkwood
Distinguished Service Professor of Medicine
University of Pittsburgh
Allison Betof Warner
Assistant Professor, Director of Melanoma Medical Oncology, Director of Solid Tumor Cellular Therapy
Stanford University
Mohammed Milhem
Oncology Section Chief
University of Iowa Healthcare
Aakrosh Ratan
Assistant Professor
University of Virginia
Amod Sarnaik
Senior Member / Full Professor
H Lee Moffitt Cancer Center and Research Institute
Changchuan Jiang
Assistant Professor
University of Texas Southwestern Medical Center
Xiaozhuo Liu
Research Associate
Roswell Park Comprehensive Cancer Center
Jose Conejo-Garcia
Duke Science and Technology Scholar
Duke Medicine
Shipra Gandhi
Emory University
James L. Chen
Ohio State University
David R. Gandara
Co-Director, Center for Experimental Therapeutics in Cancer
University of California Davis Comprehensive Cancer Center
Susanne Arnold
University of Kentucky
Jason Chesney
University of Louisville
Make your next move.
Prepare your application
Review drafts before you send them.